<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418379</url>
  </required_header>
  <id_info>
    <org_study_id>VO53.06</org_study_id>
    <nct_id>NCT00418379</nct_id>
  </id_info>
  <brief_title>Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Multi-national, Multi-centre, Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of Two Dosing Regimens of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Patients Suffering From Grass Pollen Rhinoconjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stallergenes Greer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stallergenes Greer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase III study to evaluate Long term efficacy , carry-over effect and safety of 300 IR
      sublingual Immunotherapy (SLIT) tablets in adults patients suffering from grass pollen
      rhinoconjunctivitis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Adjusted Symptom Score (AAdSS)</measure>
    <time_frame>Pollen period (average of 33.8 days) of Year 3</time_frame>
    <description>The Adjusted Symptom Score (AdSS) is a subject-specific symptom score which is adjusted for rescue medication use.
Participants assessed daily, during the Year 3 pollen period while on treatment, 6 rhinoconjunctivitis symptoms (sneezing, rhinorrhea, nasal pruritus, nasal congestion, ocular pruritus and watery eyes) each symptom is scored as follows: 0: no symptoms, 1: mild symptoms, 2: moderate symptoms, 3: severe symptoms. The sum of the 6 symptoms is the Rhinoconjunctivitis Total Symptom Score (RTSS) (range 0-18). If the subject took rescue medication on a given day, the AdSS equals the RTSS of that day or the AdSS of the day before, whichever is higher. This adjustment applies to the day of rescue medication use and the following day. Like the RTSS, the AdSS ranges from 0 to 18. The lower the score, the better the outcome.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">633</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>300 IR (4M)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 IR grass pollen allergen extract tablet, treatment starting 4 months before the pollen season</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 IR (2M)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 IR grass pollen allergen extract tablet, treatment starting 2 months before the pollen season</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300 IR (4M)</intervention_name>
    <description>300 IR grass pollen allergen extract tablet starting 4 months before the pollen season</description>
    <arm_group_label>300 IR (4M)</arm_group_label>
    <other_name>Sublingual immunotherapy tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300 IR (2M)</intervention_name>
    <description>300 IR grass pollen allergen extract tablet starting 2 months before the pollen season</description>
    <arm_group_label>300 IR (2M)</arm_group_label>
    <other_name>Sublingual immunotherapy tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sublingual placebo tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients aged 18 to 50 years

          -  Grass pollen-related allergic rhinoconjunctivitis for at least the last two pollen
             seasons

          -  Positive SPT and specific IgE values of at least Class 2 for grass pollen allergens

          -  A score of greater than or equal to 12 out of a possible 18 on the Retrospective
             Rhinoconjunctivitis Total Symptom Score (RRTSS)

        Exclusion Criteria:

          -  Patients with symptoms of rhinoconjunctivitis during the grass pollen season due to
             sensitisation to allergens other than grass pollen must not be included. Patients must
             be asymptomatic to all other allergens during the grass pollen season. Patients who
             have allergic rhinitis due to perennial allergen may not be included.

          -  Asthma requiring treatment other than beta-2 inhaled agonists.

          -  Patients who have received any desensitisation treatment for grass pollen or with any
             other allergen within the previous 5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain DIDIER, MD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Rangueil-Larrey, Toulouse, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DIDIER</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Didier A, Worm M, Horak F, Sussman G, de Beaumont O, Le Gall M, Melac M, Malling HJ. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol. 2011 Sep;128(3):559-66. doi: 10.1016/j.jaci.2011.06.022. Epub 2011 Jul 29.</citation>
    <PMID>21802126</PMID>
  </results_reference>
  <results_reference>
    <citation>Didier A, Malling HJ, Worm M, Horak F, Sussman G, Melac M, Soulié S, Zeldin RK. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy. 2013 May;43(5):568-77. doi: 10.1111/cea.12100.</citation>
    <PMID>23600548</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2007</study_first_submitted>
  <study_first_submitted_qc>January 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <results_first_submitted>January 25, 2016</results_first_submitted>
  <results_first_submitted_qc>April 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 25, 2016</results_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sublingual immunotherapy</keyword>
  <keyword>Grass pollen tablet</keyword>
  <keyword>Allergic rhinoconjunctivitis</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Patient First Visit 08 DEC 2006, Last Patient Last Visit 07 SEP 2011</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>300 IR (4M)</title>
          <description>300 IR grass pollen allergen extract tablet, treatment starting 4 months before the pollen season</description>
        </group>
        <group group_id="P2">
          <title>300 IR (2M)</title>
          <description>300 IR grass pollen allergen extract tablet, treatment starting 2 months before the pollen season</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Year 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
                <participants group_id="P2" count="207"/>
                <participants group_id="P3" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="179"/>
                <participants group_id="P3" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Any other reason not above-mentioned</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Year 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="167">22 patients withdrew between Year 1 and Year 2 treatment periods.</participants>
                <participants group_id="P2" count="159">20 patients withdrew between Year 1 and Year 2 treatment periods.</participants>
                <participants group_id="P3" count="182">22 patients withdrew between Year 1 and Year 2 treatment periods.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="155"/>
                <participants group_id="P3" count="172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Any other reason not above-mentioned</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Year 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151">8 patients withdrew between Year 2 and Year 3 treatment periods.</participants>
                <participants group_id="P2" count="148">7 patients withdrew between Year 2 and Year 3 treatment periods.</participants>
                <participants group_id="P3" count="166">6 patients withdrew between Year 2 and Year 3 treatment periods.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="146"/>
                <participants group_id="P3" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Any other reason not above-mentioned</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Year 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="145">3 patients withdrew between Year 3 and Year 4 study periods.</participants>
                <participants group_id="P2" count="141">5 patients withdrew between Year 3 and Year 4 study periods.</participants>
                <participants group_id="P3" count="156">7 patients withdrew between Year 3 and Year 4 study periods.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="142"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Any other reason not above-mentioned</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Year 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="128">14 patients withdrew between Year 4 and Year 5 study periods.</participants>
                <participants group_id="P2" count="120">16 patients withdrew between Year 4 and Year 5 study periods.</participants>
                <participants group_id="P3" count="134">20 patients withdrew between Year 4 and Year 5 study periods.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Any other reason not above-mentioned</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set Year 1 (FASY1). FASY1 included all patients who received at least one dose of the investigational product and had at least one Adjusted Symptom Score (ASS) during the pollen period while on treatment during the Year 1.</population>
      <group_list>
        <group group_id="B1">
          <title>300 IR (4M)</title>
          <description>300 IR grass pollen allergen extract tablet, treatment starting 4 months before the pollen season</description>
        </group>
        <group group_id="B2">
          <title>300 IR (2M)</title>
          <description>300 IR grass pollen allergen extract tablet, treatment starting 2 months before the pollen season</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo tablet</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="188"/>
            <count group_id="B2" value="188"/>
            <count group_id="B3" value="205"/>
            <count group_id="B4" value="581"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.9" spread="8.25"/>
                    <measurement group_id="B2" value="30.4" spread="7.57"/>
                    <measurement group_id="B3" value="30.2" spread="8.56"/>
                    <measurement group_id="B4" value="30.5" spread="8.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Adjusted Symptom Score (AAdSS)</title>
        <description>The Adjusted Symptom Score (AdSS) is a subject-specific symptom score which is adjusted for rescue medication use.
Participants assessed daily, during the Year 3 pollen period while on treatment, 6 rhinoconjunctivitis symptoms (sneezing, rhinorrhea, nasal pruritus, nasal congestion, ocular pruritus and watery eyes) each symptom is scored as follows: 0: no symptoms, 1: mild symptoms, 2: moderate symptoms, 3: severe symptoms. The sum of the 6 symptoms is the Rhinoconjunctivitis Total Symptom Score (RTSS) (range 0-18). If the subject took rescue medication on a given day, the AdSS equals the RTSS of that day or the AdSS of the day before, whichever is higher. This adjustment applies to the day of rescue medication use and the following day. Like the RTSS, the AdSS ranges from 0 to 18. The lower the score, the better the outcome.</description>
        <time_frame>Pollen period (average of 33.8 days) of Year 3</time_frame>
        <population>Full Analysis Set Year 3 (FASY3). FASY3 included all patients who received at least one dose of the investigational product and had at least one Adjusted Symptom Score (AdSS) during the pollen period while on treatment during the Year 3.</population>
        <group_list>
          <group group_id="O1">
            <title>300 IR (4M)</title>
            <description>300 IR grass pollen allergen extract tablet, treatment starting 4 months before the pollen season</description>
          </group>
          <group group_id="O2">
            <title>300 IR (2M)</title>
            <description>300 IR grass pollen allergen extract tablet, treatment starting 2 months before the pollen season</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Average Adjusted Symptom Score (AAdSS)</title>
          <description>The Adjusted Symptom Score (AdSS) is a subject-specific symptom score which is adjusted for rescue medication use.
Participants assessed daily, during the Year 3 pollen period while on treatment, 6 rhinoconjunctivitis symptoms (sneezing, rhinorrhea, nasal pruritus, nasal congestion, ocular pruritus and watery eyes) each symptom is scored as follows: 0: no symptoms, 1: mild symptoms, 2: moderate symptoms, 3: severe symptoms. The sum of the 6 symptoms is the Rhinoconjunctivitis Total Symptom Score (RTSS) (range 0-18). If the subject took rescue medication on a given day, the AdSS equals the RTSS of that day or the AdSS of the day before, whichever is higher. This adjustment applies to the day of rescue medication use and the following day. Like the RTSS, the AdSS ranges from 0 to 18. The lower the score, the better the outcome.</description>
          <population>Full Analysis Set Year 3 (FASY3). FASY3 included all patients who received at least one dose of the investigational product and had at least one Adjusted Symptom Score (AdSS) during the pollen period while on treatment during the Year 3.</population>
          <units>Units on a scale (range: 0 to 18)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" spread="0.357"/>
                    <measurement group_id="O2" value="3.25" spread="0.369"/>
                    <measurement group_id="O3" value="5.21" spread="0.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over 3 years during the treatment periods .</time_frame>
      <desc>TEAEs were defined as any AE which started on or after the administration of the investigational product (IP) in the corresponding treatment period up to 30 days after the last administration of the IP (inclusive) for the corresponding period.
Note: Serious Adverse Events and Other Adverse Events are described in the Results Publications.</desc>
      <group_list>
        <group group_id="E1">
          <title>300 IR (4M)</title>
          <description>300 IR grass pollen allergen extract tablet, treatment starting 4 months before the pollen season</description>
        </group>
        <group group_id="E2">
          <title>300 IR (2M)</title>
          <description>300 IR grass pollen allergen extract tablet, treatment starting 2 months before the pollen season</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo tablet</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 9.1.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>FAMILIAL MEDITERRANEAN FEVER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>HEPATITIS B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>GENITAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>MENISCUS LESION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>EYE INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>LIGAMENT SPRAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ARTHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BENIGN NEOPLASM OF CERVIX UTERI</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>TESTICULAR GERM CELL TUMOUR MIXED STAGE I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ECTOPIC PREGNANCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ANGIOEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ABORTION INDUCED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="167"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 9.1.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="167" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="170" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>EAR PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>EYE PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>LACRIMATION INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ORAL PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>OEDEMA MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ORAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>GLOSSODYNIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA ORAL</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>SEASONAL ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>THROAT IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>SNEEZING</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>NASAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PHARYNGOLARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>PHARYNGEAL OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="207"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Laurence Paolozzi, Medical Director</name_or_title>
      <organization>Stallergenes</organization>
      <phone>+33 (0) 1 55 59 26 33</phone>
      <email>lpaolozzi@stallergenes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

